DOCSLIB.ORG

(12) United States Patent (10) Patent No.: US 8,784.808 B2

Total Page：16

File Type：pdf, Size：1020Kb

Download full-text PDF Read full-text
(12) United States Patent (10) Patent No.: US 8,784.808 B2 USOO878.4808B2 (12) United States Patent (10) Patent No.: US 8,784.808 B2 Johnson et al. 45) Date of Patent: *J. 22,9 2014 (54) FCYRIIB SPECIFIC ANTIBODIES AND 6,180,370 B1 1/2001 Queen et al. METHODS OF USE THEREOF 6,194.551 B1 2/2001 Idusogie et al. 6,218,149 B1 4/2001 Morrison et al. (75) Inventors: Leslie S. Johnson, Darnestown, MD 6.242,195 B1 6/2001 Idusogie et al. (US); Ling Huang, Bethesda, MD (US) 6,277.375 B1 8 2001 Ward 6,300,065 B1 10/2001 Kieke et al. (73) Assignee: MacroGenics, Inc., Rockville, MD (US) 6,339,069 B1 1/2002 Meers et al. 6,420,149 B1 7/2002 Fukuda et al. 6,423.538 B1 7/2002 Wittrup et al. (*) Notice: Subject to any disclaimer, the term of this 6,455,263 B2 9/2002 Payan patent is extended or adjusted under 35 6,472,511 B1 10/2002 Leung et al. U.S.C. 154(b) by 0 days. 6,528,624 B1 3/2003 Idusogie et al. This patent is Subject to a terminal dis- 6,538,124 B1 3/2003 Idusogie et al. claimer. 6,548,640 B1 4/2003 Winter 6,696,550 B2 2/2004 Larosa et al. (21) Appl. No.: 13/367,626 6,737,056 B1 5/2004 Presta y x- - - 9 6,821,505 B2 11/2004 Ward 6,982,321 B2 1/2006 Winter (22)22) FileFiled: Feb.eD. 7,1, 2012 7.315,786- was B2 1/2008 Dahiyat et al. O O 7,317,091 B2 1/2008 Lazaret al. (65) Prior Publication Data 7,355,008 B2 4/2008 Stavenhagen et al. US 2012/0141476A1 Jun. 7, 2012 7,425,619 B2 9/2008 Koenig et al. 7,425,620 B2 9/2008 Koenig et al. O O 7,632,497 B2 12/2009 Stavenhagen Related U.S. Application Data 7,655,229 B2 2/2010 Chan et al. (60) Division of application No. 12/349,876, filed on Jan. 7, 23. R 33 s RS 2009, now Pat. No. 8,133,982, which is a continuation wwal of application No. 11/126,978, filed on May 10, 2005, (Continued) now Pat. No. 7,521,542. FOREIGN PATENT DOCUMENTS (60) Provisional application No. 60/582,043, filed on Jun. 21, 2004, provisional application No. 60/569,882, EP O 327 378 8, 1989 filed on May 10, 2004. EP O 332865 9, 1989 (Continued) (51) Int. Cl. A 6LX39/395 (2006.01) OTHER PUBLICATIONS (52) U.S. Cl. USPC ..................................... 424/130.1; 530/387.1 White et al. (2001, Ann. Rev. Med., 2001, 52:125-145).* (58) Field of Classification Search NO (Continued) See application file for complete search history. (56) References Cited Primary Examiner — Laura B Goddard Assistant Examiner — Meera Natarajan U.S. PATENT DOCUMENTS (74) Attorney, Agent, or Firm — William C. Schrot; 4,179,337. A 12/1979 Davis et al. AuerbachSchrot LLC 4,752,601 A 6, 1988 Hahn 5,024,835 A 6, 1991 Rao et al. 5,225,539 A 7, 1993 Winter (57) ABSTRACT 5,348,876 A 9, 1994 Michaelsen et al. 3: A 88: SS The present invention relates to antibodies or fragments 5,585,089 A 2, 1996 Queen et al. thereof that bind FcyRIIB with greater affinity than said anti 5,624,821 A 4, 1997 Winter et al. bodies or fragments binds FcyRIIA. The invention encom 5,648,260 A 7, 1997 Winter et al. passes the use of Such antibodies or fragments for the treat 5,824.487 A 10, 1998 Ravetch et al. 5,837.243 A 11/1998 Deo et al. ment of diseases related to loss of balance of Fc receptor 5,874,239 A 2, 1999 Schatz mediated signaling, Such as cancer, autoimmune diseases, 5,877,396 A 3, 1999 Ravetch et al. inflammatory diseases or IgE-mediated allergic disorders. 5,888,533 A 3, 1999 Dunn 5,932,433 A 8, 1999 Schatz The present invention also encompasses the use of Such anti 5,945,115 A 8, 1999 Dunn et al. bodies and fragments in combination with other cancer thera 5,985,599 A 1 1/1999 Mckenzie et al. pies, methods of enhancing the therapeutic effect of therapeu 6,019,968 A 2/2000 Platz et al. tic antibodies, and methods of enhancing efficacy of vaccine 6,025,485 A 2/2000 Kamb et al. compositions 6,114,147 A 9, 2000 Frenken et al. p 6,132,764 A 10, 2000 Li et al. 6,132,992 A 10, 2000 Ledbetter et al. 6,165,745 A 12/2000 Ward et al. 25 Claims, 5 Drawing Sheets US 8,784.808 B2 Page 2 (56) References Cited WO WO 2004/065423 8, 2004 WO WO 2004/074455 9, 2004 U.S. PATENT DOCUMENTS WO WO 2004/099.249 11, 2004 WO WO 2005/O18669 3, 2005 2001.0036459 A1 11, 2001 Ravetch WO WO 2005, O70963 8, 2005 2002, 0004587 A1 1/2002 Miller et al. WO WO 2005/110474 11, 2005 2002/0028486 A1 3f2002 Morrison et al. WO WO 2005/115452 12/2005 2003/0077282 A1 4/2003 Bigler et al. WO WO 2006/02O114 2, 2006 2003/0115614 A1 6/2003 Kanda et al. WO WO 2006/028956 3, 2006 2003/0158389 A1 8/2003 Idusogie et al. WO WO 2006/066O78 6, 2006 2003. O1903.19 A1 10, 2003 Adolfetal. WO WO 2006/088494 8, 2006 2003/0207346 A1 11/2003 Arathoon et al. WO WO 2006/113665 10, 2006 2004/0002587 A1 1/2004 Watkins et al. WO WO 2007/021841 2, 2007 2004/0110226 A1 6/2004 LaZaret al. WO WO 2007/024249 3, 2007 2004/O132101 A1 7/2004 LaZaret al. WO WO 2007/106707 9, 2007 2004/0185045 A1 9/2004 Koenig et al. WO WO 2008/OO2933 1, 2008 20040191244 A1 9, 2004 Presta WO WO 2008/OO9545 1, 2008 2004/0220388 A1 11/2004 Mertens et al. WO WO 2008/O1919.9 2, 2008 2004/0235065 A1 11/2004 Hansen et al. WO WO 2009/083009 T 2009 2005.0025764 A1 2/2005 Watkins et al. WO WO 2009,151717 9, 2009 2005, 0037000 A1 2/2005 Stavenhagen et al. 2005.0054832 A1 3/2005 LaZaret al. OTHER PUBLICATIONS 38885. A. 358. Syngeal Alfred—the Allele FREquency Database (http://alfred.med.yale. 2005/0215767 A1 9/2005 Koenig et al. edulalfredlmvograph.asp?siteuid=SI273212R): 3 pages. 2005/0260213 A1 1 1/2005 Koenig et al. Barabé, F. et al. (1998) “Crystal-Induces Neutrophil Activation VI. 2006, OO1381.0 A1 1/2006 Johnson et al. Involvement of FCYRIIIb (CD16) and CDI IB in Response to Inflam 2006, OO24298 A1 2, 2006 Lazar et al. matory Microcrystals.” FASEB J. 12:209-220. 2006, OO73142 A1 4/2006 Chan et al. Batteux, F. et al. (1999) “Fcy RII (CD32)-Dependent Induction of 2006/0134709 A1 6/2006 Stavenhagen et al. Interferon-Alpha by Serum From Patients With Lupus 2006/0177439 A1 8/2006 Koenig et al. Erythematosus.” Eur, Cytokine Netw. 10:509-513. 2007/OOO4909 A1 1/2007 Johnson et al. Bensussan, A. et al. (1995) "Detection of Membrane-Bound HLA-G 2007.0036799 A1 2/2007 Stavenhagen et al. Translated Products With a Specific Monoclonal Antibody.” Proc. 2007,0253948 A1 11, 2007 Chan et al. Natl. Acad. Sci. (U.S.A.) 92:10292-10296. 2008/0044417 A1 2/2008 Johnson et al. Calzascia Declaration in Opposition to EP 1534335 (2012), pp. 1-16. 2008 OO51563 A1 2/2008 Lazaret al. Castellis, M. et al. (1999) “Mast Cells. Molecular and Cell Biology.” 2008/0131435 A1 6/2008 Stavenhagen et al. Internet J. Asthma Immunol. 1(1) DOI: 10.5580/2797; 9 pages. 2008. O138344 A1 6/2008 Stavenhagen et al. Dako Specification Sheet KB61; 2 pages. 2008/0286819 A1 11/2008 Ravetch et al. Endogen Website (http://woerterbych.babylon.com/endogen?); 2 2009/0053218 A1 2/2009 Koenig et al. pageS. Geuijen CAW et al. (2005) "Afinity Ranking of Antibodies Using FOREIGN PATENT DOCUMENTS Flow Cytometry. Application in Antibody Phage Display-Based Tar get Discovery,” J. Immunol. Methods. 302(1-2):68-77. EP O 629 703 12/1994 Gosselin, E. et al. (1990) “The Monoclonal Antibody 41H16 Detects EP O 359096 11, 1997 the Leu 4 Responder Form of Human FcRII,” J. Immunol. 144:1817 EP O 953 639 11, 1999 1822. EP 1 OO6 183 6, 2000 EP O 343 950 10, 2000 Halverson, G.R. et al. (2001) “Immunization of Transgenic Mice for WO WO 88,07089 9, 1988 Production of MoAbs Directed at Polymorphic Blood Group Anti WO WO 89,07142 8, 1989 gens.” Transfusion 41(11): 1393-1396. WO WO92, 16562 10, 1992 Hammerling, G.J. et al. (1990) “Self Tolerance to HLA Focuses the WO WO93,22332 11, 1993 Response of Immunized HLA-Transgenic Mice on Production of Anti WO WO94, 18330 8, 1994 body to Precise Polymorphic HLA Alloantigens.” Proc. Natl. Acad. WO WO94,29351 12/1994 Sci. (U.S.A.) 87(1):235-239. WO WO95/O5468 2, 1995 Holbrook, F. et al. (2002) "Tolerization as a Tool for Generating WO WO 97.28.267 8, 1997 Novel Monoclonal Antibodies.’ Immunol. Cell Biol. 80:319-322. WO WO97,34631 9, 1997 Ierino, F.L. et al. (1993) "Mapping Epitopes of Human Fc Gamma WO WO 97/44362 11, 1997 WO WO 98.05787 2, 1998 RII (Cdw32) With Monoclonal Antibodies and Recombinant Recep WO WO 98/23289 6, 1998 tors.” J.
Load more

Recommended publications
  • Table of Contents
    ANTICANCER RESEARCH International Journal of Cancer Research and Treatment ISSN: 0250-7005 Volume 32, Number 4, April 2012 Contents Experimental Studies * Review: Multiple Associations Between a Broad Spectrum of Autoimmune Diseases, Chronic Inflammatory Diseases and Cancer. A.L. FRANKS, J.E. SLANSKY (Aurora, CO, USA)............................................ 1119 Varicella Zoster Virus Infection of Malignant Glioma Cell Cultures: A New Candidate for Oncolytic Virotherapy? H. LESKE, R. HAASE, F. RESTLE, C. SCHICHOR, V. ALBRECHT, M.G. VIZOSO PINTO, J.C. TONN, A. BAIKER, N. THON (Munich; Oberschleissheim, Germany; Zurich, Switzerland) .................................... 1137 Correlation between Adenovirus-neutralizing Antibody Titer and Adenovirus Vector-mediated Transduction Efficiency Following Intratumoral Injection. K. TOMITA, F. SAKURAI, M. TACHIBANA, H. MIZUGUCHI (Osaka, Japan) .......................................................................................................... 1145 Reduction of Tumorigenicity by Placental Extracts. A.M. MARLEAU, G. MCDONALD, J. KOROPATNICK, C.-S. CHEN, D. KOOS (Huntington Beach; Santa Barbara; Loma Linda; San Diego, CA, USA; London, ON, Canada) ...................................................................................................................................... 1153 Stem Cell Markers as Predictors of Oral Cancer Invasion. A. SIU, C. LEE, D. DANG, C. LEE, D.M. RAMOS (San Francisco, CA, USA) ................................................................................................
    [Show full text]
  • Proteomics and Drug Repurposing in CLL Towards Precision Medicine
    cancers Review Proteomics and Drug Repurposing in CLL towards Precision Medicine Dimitra Mavridou 1,2,3, Konstantina Psatha 1,2,3,4,* and Michalis Aivaliotis 1,2,3,4,* 1 Laboratory of Biochemistry, School of Medicine, Faculty of Health Sciences, Aristotle University of Thessaloniki, GR-54124 Thessaloniki, Greece; [email protected] 2 Functional Proteomics and Systems Biology (FunPATh)—Center for Interdisciplinary Research and Innovation (CIRI-AUTH), GR-57001 Thessaloniki, Greece 3 Basic and Translational Research Unit, Special Unit for Biomedical Research and Education, School of Medicine, Aristotle University of Thessaloniki, GR-54124 Thessaloniki, Greece 4 Institute of Molecular Biology and Biotechnology, Foundation of Research and Technology, GR-70013 Heraklion, Greece * Correspondence: [email protected] (K.P.); [email protected] (M.A.) Simple Summary: Despite continued efforts, the current status of knowledge in CLL molecular pathobiology, diagnosis, prognosis and treatment remains elusive and imprecise. Proteomics ap- proaches combined with advanced bioinformatics and drug repurposing promise to shed light on the complex proteome heterogeneity of CLL patients and mitigate, improve, or even eliminate the knowledge stagnation. In relation to this concept, this review presents a brief overview of all the available proteomics and drug repurposing studies in CLL and suggests the way such studies can be exploited to find effective therapeutic options combined with drug repurposing strategies to adopt and accost a more “precision medicine” spectrum. Citation: Mavridou, D.; Psatha, K.; Abstract: CLL is a hematological malignancy considered as the most frequent lymphoproliferative Aivaliotis, M. Proteomics and Drug disease in the western world. It is characterized by high molecular heterogeneity and despite the Repurposing in CLL towards available therapeutic options, there are many patient subgroups showing the insufficient effectiveness Precision Medicine.
    [Show full text]
  • Chemical Properties Biological Description Solubility
    Data Sheet (Cat.No.T4412) Roquinimex Chemical Properties CAS No.: 84088-42-6 Formula： C18H16N2O3 Molecular Weight： 308.34 Appearance： N/A Storage： 0-4℃ for short term (days to weeks), or -20℃ for long term (months). Biological Description Description Roquinimex (Linomide) is a quinoline derivative immunostimulant which increases NK cell activity and macrophage cytotoxicity; inhibits angiogenesis and reduces the secretion of TNF alpha. Targets(IC50) Others: None In vivo Prophylactic administration of DSS-treated mice with roquinimex significantly reduced clinical signs of colitis, MDS and the CH-reduction. Moreover, in roquinimex treated animals, the MPO activity was significantly reduced by more than 50% compared to DSS control mice. Notably, therapeutic administration of roquinimex in DSS-treated mice also significantly inhibited the MDS, CH-reduction and MPO activity. Linomide, a synthetic immunomodulator, at concentrations effective in vivo reduces the number of MBP-reactive TNF-alpha and increases MBP-reactive IL-10 and TGF-beta mRNA expressing MNC from MS patients' blood when analysed in vitro. Compared to dexamethasone, Linomide up-regulated levels of blood MNC expressing mRNA of TGF-beta after culture in presence of MBP Solubility Information Solubility DMSO: 83.3 mg/mL (270.17 mM) (< 1 mg/ml refers to the product slightly soluble or insoluble) Preparing Stock Solutions 1mg 5mg 10mg 1 mM 3.243 mL 16.216 mL 32.432 mL 5 mM 0.649 mL 3.243 mL 6.486 mL 10 mM 0.324 mL 1.622 mL 3.243 mL 50 mM 0.065 mL 0.324 mL 0.649 mL Please select the appropriate solvent to prepare the stock solution, according to the solubility of the product in different solvents.
    [Show full text]
  • Encapsulation of Nedaplatin in Novel Pegylated Liposomes Increases Its Cytotoxicity and Genotoxicity Against A549 and U2OS Human Cancer Cells
    pharmaceutics Article Encapsulation of Nedaplatin in Novel PEGylated Liposomes Increases Its Cytotoxicity and Genotoxicity against A549 and U2OS Human Cancer Cells 1, 2, 1 1 2, Salma El-Shafie y, Sherif Ashraf Fahmy y , Laila Ziko , Nada Elzahed , Tamer Shoeib * and Andreas Kakarougkas 1,* 1 Department of Biology, School of Sciences and Engineering, The American University in Cairo, Cairo 11835, Egypt; [email protected] (S.E.-S.); [email protected] (L.Z.); [email protected] (N.E.) 2 Department of Chemistry, School of Sciences and Engineering, The American University in Cairo, Cairo 11835 Egypt; sheriff[email protected] * Correspondence: [email protected] (T.S.); [email protected] (A.K.) These authors contribute equally to this paper. y Received: 7 April 2020; Accepted: 25 August 2020; Published: 10 September 2020 Abstract: Following the discovery of cisplatin over 50 years ago, platinum-based drugs have been a widely used and effective form of cancer therapy, primarily causing cell death by inducing DNA damage and triggering apoptosis. However, the dose-limiting toxicity of these drugs has led to the development of second and third generation platinum-based drugs that maintain the cytotoxicity of cisplatin but have a more acceptable side-effect profile. In addition to the creation of new analogs, tumor delivery systems such as liposome encapsulated platinum drugs have been developed and are currently in clinical trials. In this study, we have created the first PEGylated liposomal form of nedaplatin using thin film hydration. Nedaplatin, the main focus of this study, has been exclusively used in Japan for the treatment of non-small cell lung cancer, head and neck, esophageal, bladder, ovarian and cervical cancer.
    [Show full text]
  • Tanibirumab (CUI C3490677) Add to Cart
    5/17/2018 NCI Metathesaurus Contains Exact Match Begins With Name Code Property Relationship Source ALL Advanced Search NCIm Version: 201706 Version 2.8 (using LexEVS 6.5) Home | NCIt Hierarchy | Sources | Help Suggest changes to this concept Tanibirumab (CUI C3490677) Add to Cart Table of Contents Terms & Properties Synonym Details Relationships By Source Terms & Properties Concept Unique Identifier (CUI): C3490677 NCI Thesaurus Code: C102877 (see NCI Thesaurus info) Semantic Type: Immunologic Factor Semantic Type: Amino Acid, Peptide, or Protein Semantic Type: Pharmacologic Substance NCIt Definition: A fully human monoclonal antibody targeting the vascular endothelial growth factor receptor 2 (VEGFR2), with potential antiangiogenic activity. Upon administration, tanibirumab specifically binds to VEGFR2, thereby preventing the binding of its ligand VEGF. This may result in the inhibition of tumor angiogenesis and a decrease in tumor nutrient supply. VEGFR2 is a pro-angiogenic growth factor receptor tyrosine kinase expressed by endothelial cells, while VEGF is overexpressed in many tumors and is correlated to tumor progression. PDQ Definition: A fully human monoclonal antibody targeting the vascular endothelial growth factor receptor 2 (VEGFR2), with potential antiangiogenic activity. Upon administration, tanibirumab specifically binds to VEGFR2, thereby preventing the binding of its ligand VEGF. This may result in the inhibition of tumor angiogenesis and a decrease in tumor nutrient supply. VEGFR2 is a pro-angiogenic growth factor receptor
    [Show full text]
  • WO 2017/176265 Al
    (12) INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT) (19) World Intellectual Property Organization International Bureau (10) International Publication Number (43) International Publication Date W O 2017/176265 A l 12 October 2017 (12.10.2017) P O P C T (51) International Patent Classification: (74) Agent: COLLINS, Daniel W.; Foley & Lardner LLP, A61K 9/00 (2006.01) A61K 9/51 (2006.01) 3000 K Street, NW, 6th Floor, Washington, DC 20007- A61K 47/42 (20 ) 5109 (US). (21) International Application Number: (81) Designated States (unless otherwise indicated, for every PCT/US20 16/026270 kind of national protection available): AE, AG, AL, AM, AO, AT, AU, AZ, BA, BB, BG, BH, BN, BR, BW, BY, (22) International Filing Date: BZ, CA, CH, CL, CN, CO, CR, CU, CZ, DE, DK, DM, 6 April 2016 (06.04.2016) DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, (25) Filing Language: English HN, HR, HU, ID, IL, EST, IR, IS, JP, KE, KG, KN, KP, KR, KZ, LA, LC, LK, LR, LS, LU, LY, MA, MD, ME, MG, (26) Publication Language: English MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, (71) Applicant: MAYO FOUNDATION FOR MEDICAL PA, PE, PG, PH, PL, PT, QA, RO, RS, RU, RW, SA, SC, EDUCATION AND RESEARCH [US/US]; 200 First SD, SE, SG, SK, SL, SM, ST, SV, SY, TH, TJ, TM, TN, Street, NW, Rochester, Minnesota 55905 (US). TR, TT, TZ, UA, UG, US, UZ, VC, VN, ZA, ZM, ZW. (84) Designated States (72) Inventors: MARKOVIC, Svetomir N.; c/o Mayo Founda (unless otherwise indicated, for every tion For Medical Education And Research, 200 First kind of regional protection available): ARIPO (BW, GH, Street, NW, Rochester, Minnesota 55905 (US).
    [Show full text]
  • Stems for Nonproprietary Drug Names
    USAN STEM LIST STEM DEFINITION EXAMPLES -abine (see -arabine, -citabine) -ac anti-inflammatory agents (acetic acid derivatives) bromfenac dexpemedolac -acetam (see -racetam) -adol or analgesics (mixed opiate receptor agonists/ tazadolene -adol- antagonists) spiradolene levonantradol -adox antibacterials (quinoline dioxide derivatives) carbadox -afenone antiarrhythmics (propafenone derivatives) alprafenone diprafenonex -afil PDE5 inhibitors tadalafil -aj- antiarrhythmics (ajmaline derivatives) lorajmine -aldrate antacid aluminum salts magaldrate -algron alpha1 - and alpha2 - adrenoreceptor agonists dabuzalgron -alol combined alpha and beta blockers labetalol medroxalol -amidis antimyloidotics tafamidis -amivir (see -vir) -ampa ionotropic non-NMDA glutamate receptors (AMPA and/or KA receptors) subgroup: -ampanel antagonists becampanel -ampator modulators forampator -anib angiogenesis inhibitors pegaptanib cediranib 1 subgroup: -siranib siRNA bevasiranib -andr- androgens nandrolone -anserin serotonin 5-HT2 receptor antagonists altanserin tropanserin adatanserin -antel anthelmintics (undefined group) carbantel subgroup: -quantel 2-deoxoparaherquamide A derivatives derquantel -antrone antineoplastics; anthraquinone derivatives pixantrone -apsel P-selectin antagonists torapsel -arabine antineoplastics (arabinofuranosyl derivatives) fazarabine fludarabine aril-, -aril, -aril- antiviral (arildone derivatives) pleconaril arildone fosarilate -arit antirheumatics (lobenzarit type) lobenzarit clobuzarit -arol anticoagulants (dicumarol type) dicumarol
    [Show full text]
  • Treatment of Experimental Autoimmune Encephalomyelitis in SJL/J Mice with a Replicative HSV-1 Vector Expressing Interleukin-5
    Gene Therapy (2011) 18, 646–655 & 2011 Macmillan Publishers Limited All rights reserved 0969-7128/11 www.nature.com/gt ORIGINAL ARTICLE Treatment of experimental autoimmune encephalomyelitis in SJL/J mice with a replicative HSV-1 vector expressing interleukin-5 M Nyga˚rdas1, C Aspelin1, H Paavilainen1,MRo¨ytta¨2,MWaris1 and V Hukkanen1,3 Experimental autoimmune encephalomyelitis (EAE) is an autoimmune inflammation of the central nervous system and is used as the experimental model of multiple sclerosis (MS). The exact mechanism behind the disease is still unknown, but interleukin (IL)-17 expressing T cells are thought to mediate the disease. Toll-like receptors (TLRs) are known to have a role in the innate immune response against pathogens, and several TLRs have also a role in the disease course of EAE. Here, we show that treatment with a herpes simplex virus type 1 vector expressing the Th2 cytokine IL-5 ameliorates EAE and decreases the numbers of infiltrating lymphocytes in the brain. The effect involves downregulation of TLR 2, 3 and 9 mRNA expression and upregulation of type I interferons (IFNs) in brains during onset of disease. The elevated expression of type I IFNs was also observed during recovery. Gene Therapy (2011) 18, 646–655; doi:10.1038/gt.2011.4; published online 17 February 2011 Keywords: experimental autoimmune encephalomyelitis (EAE); Herpes simplex virus (HSV); interleukin; interferon; Toll-like receptor INTRODUCTION but helpful in understanding the role of the different cytokines. Multiple sclerosis (MS) is a demyelinating autoimmune disease of the Th2 cytokines have, for example, been used for therapy of EAE, either central nervous system (CNS), characterized by infiltration of inflam- directly administered or expressed from viral vectors.
    [Show full text]
  • The Use of Stems in the Selection of International Nonproprietary Names (INN) for Pharmaceutical Substances
    WHO/PSM/QSM/2006.3 The use of stems in the selection of International Nonproprietary Names (INN) for pharmaceutical substances 2006 Programme on International Nonproprietary Names (INN) Quality Assurance and Safety: Medicines Medicines Policy and Standards The use of stems in the selection of International Nonproprietary Names (INN) for pharmaceutical substances FORMER DOCUMENT NUMBER: WHO/PHARM S/NOM 15 © World Health Organization 2006 All rights reserved. Publications of the World Health Organization can be obtained from WHO Press, World Health Organization, 20 Avenue Appia, 1211 Geneva 27, Switzerland (tel.: +41 22 791 3264; fax: +41 22 791 4857; e-mail: [email protected]). Requests for permission to reproduce or translate WHO publications – whether for sale or for noncommercial distribution – should be addressed to WHO Press, at the above address (fax: +41 22 791 4806; e-mail: [email protected]). The designations employed and the presentation of the material in this publication do not imply the expression of any opinion whatsoever on the part of the World Health Organization concerning the legal status of any country, territory, city or area or of its authorities, or concerning the delimitation of its frontiers or boundaries. Dotted lines on maps represent approximate border lines for which there may not yet be full agreement. The mention of specific companies or of certain manufacturers’ products does not imply that they are endorsed or recommended by the World Health Organization in preference to others of a similar nature that are not mentioned. Errors and omissions excepted, the names of proprietary products are distinguished by initial capital letters.
    [Show full text]
  • Ehealth DSI [Ehdsi V2.2.2-OR] Ehealth DSI – Master Value Set
    MTC eHealth DSI [eHDSI v2.2.2-OR] eHealth DSI – Master Value Set Catalogue Responsible : eHDSI Solution Provider PublishDate : Wed Nov 08 16:16:10 CET 2017 © eHealth DSI eHDSI Solution Provider v2.2.2-OR Wed Nov 08 16:16:10 CET 2017 Page 1 of 490 MTC Table of Contents epSOSActiveIngredient 4 epSOSAdministrativeGender 148 epSOSAdverseEventType 149 epSOSAllergenNoDrugs 150 epSOSBloodGroup 155 epSOSBloodPressure 156 epSOSCodeNoMedication 157 epSOSCodeProb 158 epSOSConfidentiality 159 epSOSCountry 160 epSOSDisplayLabel 167 epSOSDocumentCode 170 epSOSDoseForm 171 epSOSHealthcareProfessionalRoles 184 epSOSIllnessesandDisorders 186 epSOSLanguage 448 epSOSMedicalDevices 458 epSOSNullFavor 461 epSOSPackage 462 © eHealth DSI eHDSI Solution Provider v2.2.2-OR Wed Nov 08 16:16:10 CET 2017 Page 2 of 490 MTC epSOSPersonalRelationship 464 epSOSPregnancyInformation 466 epSOSProcedures 467 epSOSReactionAllergy 470 epSOSResolutionOutcome 472 epSOSRoleClass 473 epSOSRouteofAdministration 474 epSOSSections 477 epSOSSeverity 478 epSOSSocialHistory 479 epSOSStatusCode 480 epSOSSubstitutionCode 481 epSOSTelecomAddress 482 epSOSTimingEvent 483 epSOSUnits 484 epSOSUnknownInformation 487 epSOSVaccine 488 © eHealth DSI eHDSI Solution Provider v2.2.2-OR Wed Nov 08 16:16:10 CET 2017 Page 3 of 490 MTC epSOSActiveIngredient epSOSActiveIngredient Value Set ID 1.3.6.1.4.1.12559.11.10.1.3.1.42.24 TRANSLATIONS Code System ID Code System Version Concept Code Description (FSN) 2.16.840.1.113883.6.73 2017-01 A ALIMENTARY TRACT AND METABOLISM 2.16.840.1.113883.6.73 2017-01
    [Show full text]
  • View Annual Report
    Spectrum Pharmaceuticals, Inc. CANCER TAKES THE LIVES OF OVER SEVEN MILLION PEOPLE WORLDWIDE EACH YEAR www.spectrumpharm.com 157 Technology Drive, Irvine, California 92618 Telephone 949.788.6700 2005 Annual Report spECTRUM PHARMACEUTicALS, INC. SPECTRUM O U R T E A M PHARMACEUTicALS BOARD OF DIRECTORS MANAGEMENT TEAM OUTSIDE COUNSEL Rajesh C. Shrotriya, M.D. Rajesh C. Shrotriya, M.D. Latham & Watkins LLP Chairman of the Board, Chief Executive Officer Chairman, Chief Executive Officer & President Costa Mesa, California is COMMITTED TO & President, Spectrum Pharmaceuticals, Inc. Luigi Lenaz, M.D. I NDEPENDENT A UDITORS Richard D. Fulmer, M.B.A. Chief Scientific Officer Kelly & Company Former Vice President, Licensing and Development, Costa Mesa, California IMPROVING THE and Vice President of Marketing, Pfizer Inc. Shyam K. Kumaria, CPA, MBA Vice President, Finance T R A N S F E R A GENT Stuart M. Krassner, Sc.D., Ph.D. U.S. Stock Transfer Corporation LIVES OF PEOPLE Professor Emeritus of Developmental and Russell L. Skibsted Glendale, California Cell Biology at the School of Biological Sciences Senior Vice President, Chief Business Officer University of California at Irvine SEC F O R M 1 0 - K Ashok Y. Gore, Ph.D. Please see the enclosed Annual Report on Form WHO ARE FIGHTING Anthony E. Maida, III, M.A., M.B.A. Senior Vice President, Pharmaceutical 10-K filed with the Securities and Exchange Chairman, BioConsul Drug Development Operations & Regulatory Compliance Commission for a more detailed description Corporation and DendriTherapeutics, Inc. of the Company’s business, financial and other Consultant to various Venture Capital, William N.
    [Show full text]
  • The Personalized Medicine Report
    THE PERSONALIZED MEDICINE REPORT 2017 · Opportunity, Challenges, and the Future The Personalized Medicine Coalition gratefully acknowledges graduate students at Manchester University in North Manchester, Indiana, and at the University of Florida, who updated the appendix of this report under the guidance of David Kisor, Pharm.D., Director, Pharmacogenomics Education, Manchester University, and Stephan Schmidt, Ph.D., Associate Director, Pharmaceutics, University of Florida. The Coalition also acknowledges the contributions of its many members who offered insights and suggestions for the content in the report. CONTENTS INTRODUCTION 5 THE OPPORTUNITY 7 Benefits 9 Scientific Advancement 17 THE CHALLENGES 27 Regulatory Policy 29 Coverage and Payment Policy 35 Clinical Adoption 39 Health Information Technology 45 THE FUTURE 49 Conclusion 51 REFERENCES 53 APPENDIX 57 Selected Personalized Medicine Drugs and Relevant Biomarkers 57 HISTORICAL PRECEDENT For more than two millennia, medicine has maintained its aspiration of being personalized. In ancient times, Hippocrates combined an assessment of the four humors — blood, phlegm, yellow bile, and black bile — to determine the best course of treatment for each patient. Today, the sequence of the four chemical building blocks that comprise DNA, coupled with telltale proteins in the blood, enable more accurate medical predictions. The Personalized Medicine Report 5 INTRODUCTION When it comes to medicine, one size does not fit all. Treatments that help some patients are ineffective for others (Figure 1),1 and the same medicine may cause side effects in only certain patients. Yet, bound by the constructs of traditional disease, and, at the same time, increase the care delivery models, many of today’s doctors still efficiency of the health care system by improving prescribe therapies based on population averages.
    [Show full text]